Drugs Made In America Acquisition Corp. (DMAAR) Retained Earnings (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Retained Earnings for 3 consecutive years, with -$7.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Retained Earnings fell 14.72% year-over-year to -$7.4 million; the trailing twelve-month figure through Jun 2026 stood at -$7.4 million (down 14.72% YoY), and the FY2025 full-year result was -$7.3 million, down 2496.1% from the prior year.
• Retained Earnings fell to -$7.4 million in Q2 2026 per DMAAR's latest filing, from -$7.3 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$279845.0 in Q4 2024 and bottomed at -$7.4 million in Q2 2026.
• Historically, Retained Earnings has averaged -$5.7 million across 3 years, with a median of -$6.6 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Retained Earnings plunged 2496.1% in 2025, then decreased 14.72% in 2026.
• Over 3 years, Retained Earnings stood at -$279845.0 in 2024, then slumped by 2496.1% to -$7.3 million in 2025, then declined by 1.96% to -$7.4 million in 2026.
• According to Business Quant data, Retained Earnings over the past three periods registered -$7.4 million, -$7.3 million, and -$6.7 million for Q2 2026, Q4 2025, and Q3 2025 respectively.